KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-2807
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location ; day:27 ; month:6 ; year:2020 ; pages:1-12
Pathology & oncology research ; (27.6.2020), 1-12
- Urheber
-
Tabuso, M.
Christian, M.
Kimani, P. K.
Gopalakrishnan, K.
Arasaradnam, R. P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12253-020-00850-y
- URN
-
urn:nbn:de:101:1-2020082321325909385519
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tabuso, M.
- Christian, M.
- Kimani, P. K.
- Gopalakrishnan, K.
- Arasaradnam, R. P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
Bony tumour in an unusual location on the mandible
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
The impact of KRAS mutations on VEGF-A production and tumour vascular network
Kras
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
Bony tumour in an unusual location on the mandible
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
The impact of KRAS mutations on VEGF-A production and tumour vascular network
Kras
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
Bony tumour in an unusual location on the mandible
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
The impact of KRAS mutations on VEGF-A production and tumour vascular network